Beginner's Mind

Christian Soschner
  • 5,0 (5)
  • FIRMENGRÜNDUNG
  • MONATLICH

Blueprints for Builders and Investors Hosted by Christian Soschner From pre-seed to post-IPO, every company—especially in deep tech, biotech, AI, and climate tech—lives or dies by the frameworks it follows. On Beginner’s Mind, Christian Soschner uncovers the leadership principles behind the world’s most impactful companies—through deep-dive interviews, strategic book reviews, and patterns drawn from history’s greatest business, military, and political minds. With over 200 interviews, panels, and livestreams, the show ranks in the Top 10% globally—and is recognized as the #1 deep tech podcast.  With 35+ years across M&A, company building, board roles, business schools, ultrarunning, and martial arts, Christian brings a rare lens: What it really takes to turn breakthrough science into business—how to grow it, lead it, and shape the world around it. 🎙 Expect each episode to deliver: Founder & Investor Blueprints: How breakthrough technologies scale from lab to IPOHistorical & Biographical Frameworks: Timeless playbooks from the world's great buildersLeadership & Communication Mastery: Tools to inspire, persuade, and lead at scale Whether you're building the next biotech success, investing in AI, or leading a climate tech company through hypergrowth—this podcast gives you the edge. Listen in. Apply what matters. Build companies that last. 📬 Join the newsletter & community: https://lsg2g.substack.com/

  1. EP 168 - Alasdair Milton: The Innovation Inflection Point: Why 70% of Cures Never Reach Patients

    30.12.2025

    EP 168 - Alasdair Milton: The Innovation Inflection Point: Why 70% of Cures Never Reach Patients

    Breakthrough science has never been stronger — yet patients still miss life-saving therapies. Despite decades of innovation, most precision medicines fail at the last mile of healthcare delivery. The problem isn’t discovery. It’s how science, capital, and systems are aligned — or not. Possessing elite science is no longer enough to win in the multi-trillion-dollar biopharma ecosystem. As innovation shifts from West to East and from treatment to prevention, leadership teams struggle to bridge scientific depth with incentives, execution, and real-world delivery. Capital follows speed and scale — not intention — and healthcare systems built decades ago are failing to keep up. In this episode, Alasdair Milton, Principal at KPMG, explains where innovation actually breaks — and what must change for cures to reach patients at scale. From diagnostics and data silos to capital allocation and prevention models, this conversation reframes the next decade of precision medicine. 💡 What You’ll Learn in This Episode 1️⃣ Why only a fraction of eligible patients receive precision therapies 2️⃣ How delivery systems — not science — kill innovation outcomes 3️⃣ Why prevention is the next major value shift in healthcare 4️⃣ How capital allocation decisions quietly determine patient access 5️⃣ What leaders must change now to compete in the next biopharma cycle 👤 About Alasdair Milton Alasdair Milton is a Principal at KPMG advising global biopharma leaders on strategy, transactions, and innovation models. With a PhD in cancer biology and two decades at the intersection of science and capital, he works with executives navigating precision medicine, prevention, and large-scale healthcare transformation. 💬 Quotes That Reframe the Debate (01:00:20) “Great science only creates value when translated into clear commercial decisions.” (01:37:24) “Power has swung decisively to pharma, with biotechs now starved for capital and leverage.” (01:36:10) “Markets shift fast, but leverage always follows capital, data, and disciplined execution.” (02:26:30) “Life sciences must move from treating sickness to predicting risk and sustaining lifelong wellness.” (01:46:24) “China is catching up fast, and by the 2030s, truly innovative molecules may originate there.” 🧭 Timestamps (00:04:04) Shifting from treating disease to preventing it (00:05:32) Turbulent markets, steady scientific progress (00:07:03) In-vivo CAR-T and the next leap in cellular medicine (00:11:00) From chronic disease management to functional cures (00:20:20) Bridging specialized science with corporate strategy (00:21:55) Translating lab precision into business language (00:22:07) Bridging scientific depth to business acumen (00:57:40) Turning complex science into decisive commercial implications (01:08:46) Why in-person collaboration still drives leadership and learning (01:11:48) Navigating the $200B biopharma patent cliff through M&A (01:17:25) Capital concentrates on de-risked teams with proven leadership (01:18:17) Interpreting the biotech market recovery and tailwinds (01:28:26) Long-term capital returns as pharma reclaims deal leverage (01:38:03) Navigating IRA impacts and macro headwinds (01:43:39) China’s rapid ascent in the global monoclonal pipeline (01:46:24) China accelerates the eastward shift in global innovation (02:07:31) Precision medicine redefines individualized healthcare outcomes (02:09:03) Standardi Send us a text Support the show Join the Podcast Newsletter: Link

    2 Std. 42 Min.
  2. #167: Pattern Breakers — 7 Laws Behind Category-Defining Companies

    15.12.2025

    #167: Pattern Breakers — 7 Laws Behind Category-Defining Companies

    Most founders obsess over ideas. Breakthrough companies obsess over inflections, conviction, and structure. This episode unpacks Pattern Breakers by Mike Maples Jr.—a book that quietly explains why most startups never break out… and why a small minority reshape entire categories. But this isn’t a book summary. It’s a thinking upgrade for founders, operators, board members, and investors navigating the most fragile phase of company building: Series A to IPO, where timing, conviction, and structure matter more than features or pitch decks. Across seven tightly structured lessons, this episode explores how pattern-breaking companies are built before the world is ready for them—and why success is rarely about genius ideas, and almost always about seeing the future early and designing for it deliberately. You’ll hear why: breakthroughs start with external inflections, not internal brainstormingwinning companies are non-consensus and right, long before they’re popularmovements outperform products when markets get noisyMVPs test interest, but prototypes test desperationproductive disagreeableness protects insight when pressure risescorporate success quietly creates biases that kill innovationand why structure—not culture—is the hidden lever behind breakthroughsEach lesson is grounded in real company examples, translated into today’s market reality, and finished with coaching questions you can use immediately—in leadership meetings, boardrooms, or investment decisions. Key Takeaways Inflections Beat Ideas Breakthrough timing comes from external change, not creativity. Non-Consensus Is the Signal If everyone agrees, upside is already gone. Movements Outrun Products Identity compounds longer than features. Test Desperation, Not Interest Scalability starts with craving, not curiosity. Protect Conviction Consensus feels safe. It rarely creates breakthroughs. Design for Breakthroughs Small, protected, fast teams outperform bureaucracy every time. Timestamps (00:00) Intro (02:58) The Big Idea Behind Pattern Breakers (05:19) Who Is Mike Maples — and Why His Perspective Matters (07:35) Lesson 1: Start With Inflections, Not Ideas (12:36) Lesson 2: Be Non-Consensus and Right (17:31) Lesson 3: Prototype the Future, Not the MVP (21:31) Lesson 4: Recruit, Lead, and Scale Through Movements (26:20) Lesson 5: Master Productive Disagreeableness (30:04) Lesson 6: Break the Corporate Biases That Kill Breakthroughs (35:00) Lesson 7: Structure for Breakthrough Execution (39:41) Key Takeaways — The Lenses and Habits That Matter (42:21) Personal Reflection & Critique  Why Listen Learn how category-defining companies are built before markets openUpgrade how you evaluate startups, strategies, and leadership teamsReplace product thinking with inflection, conviction, and structureWalk away with questions that immediately sharpen decisionsFound this valuable? Like, share, and follow. Every signal helps grow the show—and brings you more thinking frameworks from people and companies who didn’t follow patterns… they broke them. Send us a text Support the show Join the Podcast Newsletter: Link

    47 Min.
  3. SPARK20 – 156: Janos Pasztor | The Climate Diplomat Who Refuses to Give Up on Humanity

    23.11.2025

    SPARK20 – 156: Janos Pasztor | The Climate Diplomat Who Refuses to Give Up on Humanity

    The world has grown quiet about climate change. Too quiet. We scroll past floods, fires, droughts… and move on with our day. As if the problem solved itself. As if we’ve earned the luxury to look away. Janos Pasztor (full episode) has spent 40 years inside the rooms where climate decisions are made — from serving as UN Assistant Secretary-General for Climate Change to advising presidents, prime ministers, and global institutions. And in this SPARK20 highlight episode, one truth stood out: We are not done with climate change. We are only entering its most consequential chapter. This is not a doom story. It is the story of a man who still believes humanity can choose a better future — if we’re willing to face the questions we’ve been avoiding. What You’ll Learn in 20 Minutes Why global warming accelerates even as we reduce emissions (00:01:15)  And why governments are still “not addressing the issue sufficiently.” Why adaptation alone cannot save us (00:01:54)  And what the real limits of adaptation look like. Why Janos believes we may need to cool parts of the planet (00:02:32)  And why no political leader wants to say it out loud. How climate diplomacy changed since the 1980s — and why it matters now (00:03:32)  Including the rise of China in global negotiations. Why capitalism itself may need to evolve (00:08:05)  And what this means for investors, innovation, and global stability. What geoengineering really is (and is not) (00:09:16)  Forget the internet myths — this is the factual explanation. Why volcanic eruptions hold a clue to future climate solutions (00:12:04)  Why SRM is scientifically feasible — and politically dangerous (00:17:11)  The technology is simple. The governance is not. Why the biggest risk of SRM is not cost — but consent (00:17:44)  And what happens when societies don’t get a say. What a unilateral climate intervention could trigger (00:20:33)  A scenario every policymaker should hear. Why Janos still believes in a brighter future (00:21:07)  A rare moment of optimism from someone who has seen every side of the crisis. Quotes to Carry With You 📌 “Global temperatures continue to rise — and the world is not ready.” (00:01:15) 📌 “We must consider whether the time has come to start cooling parts of the planet.” (00:02:32) 📌 “Three degrees of warming is cuckoo land. You simply cannot adapt to that.” (00:18:23) 📌 “Technology is not the issue. It’s cheap. The real question is: do societies want this?” (00:17:11) 📌 “I wouldn’t be here if I didn’t believe we can still get this right.” (00:21:07) Why This Conversation Matters Because climate change isn’t a chapter we finished. It’s the foundation on which every other chapter of the future will be written — our economies, our food systems, our borders, our investments, and the lives of our children. And while Elon Musk may one day take humans to Mars, no one alive today will move there. This planet is the one we must keep habitable. Janos Pasztor is a reminder that realism and hope are not opposites — they’re partners. 👉 Listen now. Share it fo Send us a text Support the show Join the Podcast Newsletter: Link

    25 Min.
  4. EP 166 - Karl Nehammer: Why Europe Fails to Scale – And How the EIB Plans to Fix It

    06.11.2025

    EP 166 - Karl Nehammer: Why Europe Fails to Scale – And How the EIB Plans to Fix It

    Europe leads the world in discovery — yet too often, its breakthroughs never become global companies. Billions in research funding turn into patents, not products. While others build empires from ideas, Europe risks becoming the world’s laboratory — brilliant, but broke. That’s the paradox at the heart of this conversation. In this episode, Karl Nehammer, Vice-President of the European Investment Bank (EIB) and former Chancellor of Austria, joins Christian Soschner live at BIO-Europe 2025 to discuss how Europe can turn its world-class science into world-class companies. He shares how leadership forged in crisis can rebuild confidence, competitiveness, and growth — and why every crisis hides an opportunity to start thinking differently. 💡 What You’ll Learn in This Episode 1️⃣ Why Europe’s innovation system struggles to turn discovery into scale 2️⃣ How the EIB can bridge the gap between science, capital, and market impact 3️⃣ Lessons from leading through COVID-19, the energy crisis, and diplomatic challenges 4️⃣ Why changing culture and regulation is key to Europe’s competitiveness 5️⃣ The mindset Europe needs to move from surviving to building 💬 Quotes from Karl Nehammer (00:03:33) “Every crisis is also maybe a chance — you learn a lot, decide quickly, and think in totally new ways.” (00:07:00) “We have the knowledge now of what we must change — it’s a window of opportunity.” (00:20:03) “Empower yourself. Don’t wait for another person — you can do it yourself.” 🧭 Timestamps (00:00:00) Opening – Why Europe Struggles to Scale (00:03:33) Karl Nehammer – Leadership Lessons from Crisis (00:06:21) Europe’s Innovation Challenge – Science vs. Commercialization (00:09:17) Life-Science Resilience – Lessons from COVID-19 (00:12:52) A Realistic Vision for Europe’s Future (00:17:05) Inside the European Investment Bank – Building Bridges Between Capital and Innovation (00:18:59) Empowering Founders – Karl Nehammer’s Message to Europe’s Builders (00:20:14) Closing – Optimism, Collaboration, and Confidence 🎙️ Beginner’s Mind Top 10% globally. The leading podcast for founders, investors, and policymakers shaping the future of biotech, deep tech, and innovation. Follow the show to explore more conversations like this one — where science meets strategy and leadership builds the future. Send us a text Support the show Join the Podcast Newsletter: Link

    20 Min.
  5. EP 165 – Jason Foster: 153 Rejections Later — What Every Founder Must Learn About Resilience

    28.10.2025

    EP 165 – Jason Foster: 153 Rejections Later — What Every Founder Must Learn About Resilience

    Most founders dream of raising millions. Few survive the 153 “no’s” it takes to get there. Behind every biotech breakthrough lies exhaustion — late-night calls, failed rounds, and investors who walk away at the finish line. What separates the ones who make it isn’t luck or timing — it’s resilience built into process. In this episode, Jason Foster, CEO of Ori Biotech, shares how he transformed relentless rejection into a billion-dollar trajectory. From rebuilding cell-therapy manufacturing to leading global teams through economic storms, Jason reveals how founders can systematize grit, master storytelling, and survive when everything seems to fall apart. You’ll learn how to navigate fundraising winters, why leadership begins with self-care, and how to build companies that endure long after the hype fades.  If you’ve ever doubted your path as a builder, this conversation will remind you that resilience is not a trait — it’s a practice. 💡 What You’ll Learn in This Episode 1️⃣ The real reason most founders fail long before capital runs out 2️⃣ How to turn rejection into momentum using process and habit 3️⃣ Why storytelling is the most underrated skill in biotech leadership 4️⃣ How resilience and self-care directly drive performance and valuation 5️⃣ The mindset that separates enduring companies from short-term success 👤 About Jason Foster Jason Foster is the CEO of Ori Biotech, a leading innovator transforming cell and gene therapy manufacturing. With 20+ years in global health, he has raised over $140M, led companies through IPO-level growth, and serves as a mentor and investor to emerging founders in life sciences. His mission: make advanced therapies accessible to every patient, everywhere. 💬 Quotes That Might Change How You Think (00:14:09) “There are cures for cancer today, but patients can’t reach them — access must change.”  (00:37:22) “The science is extraordinary — but if we can’t make it at scale, it means nothing.”  (01:22:17) “Purpose, not money, drives talent to transform lives through innovation.”  (01:46:17) “Fundraising is a war of attrition — constant rejection tests your resilience more than your idea.”  (02:02:16) “You only have to get up one more time than you’re knocked down.”  🧭 Timestamps to Explore (00:02:00) Embracing Hard Challenges — How Biotech Founders Build Resilience That Lasts (00:13:40) The Unacceptable Truth: Cures Exist, Yet Patients Still Can’t Access Them (00:26:23) Navigating Cultures — What European and American Biotech Leaders Can Learn From Each Other (00:32:52) Why Great Science Isn’t Enough Without Commercial Viability (00:39:19) Revolutionizing Cell Therapy Manufacturing — The Seven-Day Bottleneck Explained (00:50:11) Automation and Digitization — Unlocking Scalable Patient Access in Cell and Gene Therapy (01:09:30) Rethinking Capacity Utilization — Making Regional Biotech Manufacturing Centers Work (01:14:27) Mass Personalization — The Future Delivery Model for Advanced Therapies (01:23:00) Purpose-Driven Talent — The Secret to Retaining Top Biotech Performers (01:32:18) Fundraising as a War of Attrition — Building Vision Alignment With Investors (01:39:14) Building Investor Trust Before You Need It — A Founder’s Long Game (01:47:23) Resilience Transforms Rejection Into Triumph — Lessons From 153 Investor “No’s” 🎙️ Beginner’s Mind Top 10% globally. The Send us a text Support the show Join the Podcast Newsletter: Link

    2 Std. 7 Min.
  6. EP 164 - Kat Kozyrytska: AI in Pharma Is a Yesterday Problem – Why Ethical Frameworks Can’t Wait

    03.10.2025

    EP 164 - Kat Kozyrytska: AI in Pharma Is a Yesterday Problem – Why Ethical Frameworks Can’t Wait

    Imagine waking up to find your company’s most valuable IP leaked—not by hackers, but by the very AI tools you trusted. This isn’t a distant scenario; it’s happening inside pharma and biotech right now. And the cost isn’t just financial—it’s patient lives, broken trust, and an industry on the edge of losing credibility.  In this episode, Kat Kozyrytska shares how leaders can act before invisible risks become catastrophic. From her personal journey in post-Soviet Ukraine to building frameworks in global biotech, Kat reveals why “yesterday problems” with AI demand urgent attention today. You’ll learn how data privacy failures propagate quietly, why embedding organizational values into AI is essential, and how collaboration across companies can safeguard innovation and accelerate therapies.  The future of biotech won’t be secured by hype or speed—but by trust, ethics, and the courage to act before it’s too late.  🎧 What You’ll Learn in This Episode 1️⃣ Why “yesterday problems” with AI in pharma are already costing billions 2️⃣ How data privacy failures silently erode trust, IP, and patient safety 3️⃣ The difference between collaboration and competition in biotech innovation 4️⃣ Why embedding organizational values into AI is no longer optional 5️⃣ The future of drug discovery, clinical trials, and manufacturing in an AI-first world  👤 About Kat Kozyrytska Kat Kozyrytska is the Founder of the Cell Therapy Manufacturability Program and a global thought leader at the intersection of biotech and AI. With roots in Ukraine and a career spanning MIT, Stanford, Thermo Fisher, Sartorius, and global biotech startups, she bridges technical depth with ethical foresight.  💬 Quotes That Might Change How You Think (00:14:50) "AI can amplify good or bad behaviors — the choice is ours." (00:38:14) "Discovering dark personalities is like learning Santa isn’t real — traumatic, but suddenly everything makes sense." (01:03:26) "AI speaks with absolute confidence, but confidence is not the same as truth." (01:20:22) "AI gives us a rare chance to embed ethics and values into innovation." (01:57:01) "If personalized therapies work better, we have an ethical duty to deliver them."  🧭 Timestamps to Explore (00:05:16) From Math to Medicine – Kat’s unexpected path from equations to biotech leadership (00:09:38) Inside a Nobel Lab – How neuroscience breakthroughs shaped her ethical lens (00:12:27) Shadow AI – Why biotech leaders can’t wait to govern hidden systems (00:23:03) Data Sharing Paradox – Collaboration vs confidentiality in pharma innovation (00:31:31) Neurobiology of Manipulation – How dark personalities exploit human trust (00:41:18) Hidden Privacy Risks – What your everyday data footprint really reveals (00:52:17) Soviet Control vs American Individualism – Lessons for AI governance today (00:57:30) The Danger of One Answer – Why converging on a single AI truth is risky (01:02:51) Confidence ≠ Expertise – Rethinking how we trust AI in science (01:18:16) Embedding Core Values – How leaders can align AI with human ethics (01:51:28) Breaking Down Silos – The future of collaborative drug discovery with AI (02:14:39) Biotech 2035 – Kat’s optimistic vision for an ethical AI future  🎙️ Beginner’s Mind Top 10% globally. The leading podcast for VCs, operators, and anyone obsessed with building what comes n Send us a text Support the show Join the Podcast Newsletter: Link

    2 Std. 20 Min.
  7. #163: The NVIDIA Way — 7 Scaling Lessons from Jensen Huang’s Playbook

    14.09.2025

    #163: The NVIDIA Way — 7 Scaling Lessons from Jensen Huang’s Playbook

    Most founders obsess over products. Jensen Huang built a $3 trillion company by obsessing over inevitabilities.  This episode unpacks The NVIDIA Way by Tae Kim—the definitive account of how NVIDIA went from near-death startup to the world’s most valuable chipmaker. More than a history, it’s a manual for founders and VCs navigating the messy, high-stakes stretch between Series A and IPO.  But this isn’t just about NVIDIA.  It’s about you—if you’re scaling in deep tech, where survival depends less on genius inventions and more on how you engineer resilience, culture, and urgency into your system.  I walk you through 7 scaling lessons that matter now—from why pain is a founder’s greatest teacher to how vision and culture become moats no competitor can copy. Each principle is grounded in NVIDIA’s story, translated into today’s market reality, and wrapped with coaching prompts you can act on this week.  Key Takeaways:  Pain Builds Resilience: Intelligence helps, but scars compound faster.Reputation Is Currency: Your first product isn’t a chip or an app—it’s trust.Defy the Innovator’s Dilemma: Don’t chase quarters—build inevitabilities.Lead with Context: Replace bottlenecks with clarity and extreme ownership.Sell the Vision: Markets follow narratives, not features.Culture Outruns Capital: Execution habits compound longer than cash.Urgency Wins: Complacency kills more companies than competition.Timestamps: (00:00) Why This Episode Matters (02:18) The Big Idea of The NVIDIA Way by Tae Kim (04:36) Who is Tae Kim? (08:15) Lesson #1: Pain and Suffering Are the Recipe for Greatness (12:35) Lesson #2: Your Reputation Is Your Currency (17:05) Lesson #3: The Innovator’s Dilemma Will Come for You (21:45) Lesson #4: Lead With Context, Not Control (25:18) Lesson #5: Don’t Just Sell the Product—Sell the Vision (30:00) Lesson #6: Culture Outruns Capital—and the Competition (34:32) Lesson #7: Build Urgency Into the System (38:30) Key Takeaways—3x Reading + 25 Years in Public Markets, VC, and Scaling Deep Tech (41:24) Reflection Why Listen: Learn how NVIDIA survived near-death and built inevitabilities that defined AI.Get 7 leadership and culture principles designed for Series A–IPO scale-ups.See how to evaluate companies not by products, but by the systems that endure.Upgrade your founder or investor lens with actionable coaching questions. Found this valuable? Like, share, and follow.  Every signal grows the show—and helps bring you more playbooks from the world’s most resilient companies.    🎙️ - Beginner's Mind. Top 10% global. #1 deep tech podcast. 200+ episodes.   Send us a text Support the show Join the Podcast Newsletter: Link

    47 Min.
  8. Marc Penkala | Why Being Wrong is the Secret to Venture Success (SPARK20 – 139)

    22.08.2025

    Marc Penkala | Why Being Wrong is the Secret to Venture Success (SPARK20 – 139)

    How do you succeed in a business where being wrong is the norm? Marc Penkala has lived both sides of the table: as an entrepreneur who built, sold, and failed with companies—and now as a venture capitalist running his own fund. What makes his story different is the radical honesty about what actually drives success in venture: failure, timing, and taking risks that look stupid at first. This Spark20 episode distills Marc’s hard-earned lessons into a 20-minute masterclass for founders, investors, and policymakers navigating uncertainty. What you’ll learn Why timing, not brilliance, often decides who wins.Why failure is the ultimate credibility builder for investors.How European founders hold themselves back—and what mindset shift is overdue.Why down markets are the best time to build companies.How the “stupidest ideas” sometimes create the biggest outliers.Timestamps & Quotes 📌 (00:00:38) Entrepreneur → VC “My route into venture capital felt like a paid executive MBA… I built, I sold, I bankrupted, and then I joined the so-called evil side to truly understand investors.” 📌 (00:03:31) Failure as Fuel “Failure is the bigger success… many of my failures turned into the best things that ever happened.” 📌 (00:05:32) Credibility Through Scars “If I had never built a company, how could I authentically tell a founder I can help them?” 📌 (00:07:29) Wrong = Right in Venture “As a VC, you’re more often wrong than right. And strangely, the more you’re wrong, the higher your actual output.” 📌 (00:10:38) When Tourists Arrive, Leave “The moment angels and LPs with no clue flood the market, you literally have to stop investing. That’s when the tourists arrive.” 📌 (00:12:22) Outliers Make the Portfolio “One angel had ten bets—two of them gorillas and Tier. Didn’t matter what else he had—the outliers alone defined him.” 📌 (00:13:02) Europe vs. US Mindset “US startups think in billions. European startups think in millions. That mentality shift is everything.” 📌 (00:15:02) Stupid Ideas Win “If everyone agrees it’s a great deal, don’t do it. The best investments sound like the stupidest idea at first.” 📌 (00:17:42) Why Down Markets Build Giants “In down markets, founders get humble, go back to fundamentals, and focus on capital efficiency. That’s why the best companies come from downturns.” This isn’t just a highlight reel—it’s a reminder that in venture capital and entrepreneurship, the rules are upside down. Being wrong isn’t a weakness—it’s proof you’re taking the swings that matter. 👉 Listen now, and share it with someone who needs to think bigger. 🎙️ With over 200 interviews, panels, and livestreams, Beginner’s Mind ranks in the Top 10% globally—and is recognized as the leading deep tech podcast for Send us a text Support the show Join the Podcast Newsletter: Link

    20 Min.
Alle anzeigen (212)

5
von 5
5 Bewertungen

Info

Blueprints for Builders and Investors Hosted by Christian Soschner From pre-seed to post-IPO, every company—especially in deep tech, biotech, AI, and climate tech—lives or dies by the frameworks it follows. On Beginner’s Mind, Christian Soschner uncovers the leadership principles behind the world’s most impactful companies—through deep-dive interviews, strategic book reviews, and patterns drawn from history’s greatest business, military, and political minds. With over 200 interviews, panels, and livestreams, the show ranks in the Top 10% globally—and is recognized as the #1 deep tech podcast.  With 35+ years across M&A, company building, board roles, business schools, ultrarunning, and martial arts, Christian brings a rare lens: What it really takes to turn breakthrough science into business—how to grow it, lead it, and shape the world around it. 🎙 Expect each episode to deliver: Founder & Investor Blueprints: How breakthrough technologies scale from lab to IPOHistorical & Biographical Frameworks: Timeless playbooks from the world's great buildersLeadership & Communication Mastery: Tools to inspire, persuade, and lead at scale Whether you're building the next biotech success, investing in AI, or leading a climate tech company through hypergrowth—this podcast gives you the edge. Listen in. Apply what matters. Build companies that last. 📬 Join the newsletter & community: https://lsg2g.substack.com/

Informationen

  • Erstellt von
    Christian Soschner
  • Jahre aktiv
    2020 - 2025
  • Folgen
    212
  • Bewertung
    Unbedenklich
  • Copyright
    © 2025 Christian Soschner
  • Sendungswebsite
    Beginner's Mind

Das gefällt dir vielleicht auch